sponsored
PatientsVille.com Logo

PatientsVille

Metoprolol Tartrate Medical Research Studies

Up-to-date List of Metoprolol Tartrate Medical Research Studies

What Research is Being Done?

A clinical study involves research using human volunteers (also called participants) that is intended to add to medical knowledge. There are two main types of clinical studies: clinical trials (also called interventional studies) and observational studies. Following list includes both interventional and observational studies.

Latest Metoprolol Tartrate Medical Research Studies

Rank Status Study
1 Unknown  Identification of Cardiovascular Risk Factors Linked to Renal Failure Progression
Condition: Chronic Renal Failure
Intervention:
Outcome Measures: description of osteoprotegerin levels according to chronic Renal Failure progression;   calcium score description according to chronic Renal Failure progression;   osteoprotegerin description according to calcium score;   relationship between cardiovascular risk factors and calcium score;   relationship between cardiovascular risk factors and cardiovascular disease
2 Unknown  Study of Heat Shock Proteins as Prognostic Factor of Acute Renal Failure in Children (HSP-Study)
Condition: Kidney Failure, Acute
Intervention:
Outcome Measure: Acute renal failure.
3 Unknown  Fondaparinux in Critically Ill Patients With Renal Failure
Condition: Venous Thromboembolism
Intervention: Drug: Fondaparinux
Outcome Measures: Efficacy of the adjusted dose in achieving peak and trough levels similar to patients without Renal Failure;   Safety
4 Recruiting Renal Sympathetic Modification in Patients With Chronic Renal Failure
Condition: Chronic Renal Failure
Intervention: Procedure: renal sympathetic modification
Outcome Measures: the incident of uremia and dialysis requirement;   serum creatinine increases into multiples in 1 month follow-up;   effect of urine microalbumin, urine microalbumin/creatinine, serum creatinine, or 24 hrs urine protein value;   incidence of composite cardiovascular events
5 Unknown  Development and Validation of an Enhanced Prediction Score for Postoperative Acute Renal Failure After Liver Resection
Condition: Acute Renal Failure
Intervention:
Outcome Measures: Development of an enhanced prediction score for ARF;   Decision curve analysis;   internal validation of the enhanced prediction score
6 Recruiting Pharmacokinetic Study of Buparlisib in Subjects With Renal Impairment.
Condition: Renal Impairment
Intervention: Drug: Buparlisib
Outcome Measures: Plasma pharmacokinetic (PK) parameter Cmax;   Plasma PK parameter AUCinf;   Plasma PK parameter AUC0-t;   Plasma PK parameter CL/F;   Urine PK parameter CLR;   Plasma PK parameter Tmax;   Plasma PK parameter T1/2;   Plasma PK parameter Vz/F;   Plasma Protein Binding;   Unbound plasma PK parameter Cmax,u;   Unbound plasma PK parameter AUCinf,u;   Unbound plasma PK parameter Vu/F;   Unbound plasma PK parameter CLu/F;   Urine PK parameter Ae0-t;   Relationship between PK parameters Cmax, AUCinf, AUC0-t, CL/F, urine CLR and renal function.;   Adverse Events severity and frequency;   Change from baseline in laboratory parameters;   Change from baseline in ECG parameters;   Unbound plasma PK parameter AUC0-t,u
7 Unknown  Qutenza for Critical Ischaemia in End Stage Renal Failure
Conditions: End Stage Renal Failure;   Neuropathic Pain
Intervention: Drug: QUTENZA
Outcome Measures: Chronic neuropathic pain;   Neuropathic pain;   Quality of Life;   Safety and tolerability
8 Not yet recruiting A Study to Evaluate the Pharmacokinetics Of Sativex® in Subjects With Severe Renal Impairment or End Stage Renal Disease, Compared to Matched Subjects With Normal Renal Function.
Condition: To Determine if, and to What Extent, Renal Insufficiency or Chronic Kidney Failure Affects the Pharmacokinetic Profile of Sativex
Intervention: Drug: Sativex
Outcome Measures: Pharmacokinetic parameters of THC: Cmax, AUC(0-t) and AUC(0-∞);   Pharmacokinetic parameters of 11-hydroxy-THC (11-OH-THC): Cmax, AUC(0-t) and AUC(0-∞);   Pharmacokinetic parameters of CBD: Cmax, AUC(0-t) and AUC(0-∞);   Pharmacokinetic parameters of 7-hydroxy-CBD (7-OH-CBD): Cmax, AUC(0-t) and AUC(0-∞);   Pharmacokinetic parameters of THC: t(1/2), tmax, CL/F, CLr and F(e,u);   Pharmacokinetic parameters of 11-OH-THC: t(1/2), tmax, CLr and F(e,u);   Pharmacokinetic parameters of CBD: t(1/2), tmax, CL/F, CLr and F(e,u);   Pharmacokinetic parameters of 7-OH-CBD: t(1/2), tmax, CLr and F(e,u);   Pharmacokinetic parameters of THC: Cmax(u), AUC(0-t(u)), AUC(0-∞(u)) and CLu/F;   Pharmacokinetic parameters of 11-OH-THC: Cmax(u), AUC(0-t(u)) and AUC(0-∞(u));   Pharmacokinetic parameters of CBD: Cmax(u), AUC(0-t(u)), AUC(0-∞(u)) and CLuF;   Pharmacokinetic parameters of 7-OH-CBD: Cmax(u), AUC(0-t(u)) and AUC(0-∞(u));   The incidence of adverse events as a measure of subject safety;   The number of subjects with a clinically significant change in physical and oral examination results, relative to pre-treatment baseline;   The number of subjects with a clinically significant change in 12-lead electrocardiogram (ECG) results, relative to pre-treatment baseline;   The number of subjects with clinically significant changes in laboratory test parameters, relative to pre-treatment baseline;   The number of subjects with a clinically significant change in vital signs, relative to pre-treatment baseline
9 Recruiting Study Of Palbociclib (PD-0332991) In Renal Impairment
Condition: Renal Impairment
Intervention: Drug: palbociclib
Outcome Measures: Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0 - 8)];   Maximum Observed Plasma Concentration (Cmax);   Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast);   Apparent Oral Clearance (CL/F);   Time to Reach Maximum Observed Plasma Concentration (Tmax);   Apparent Volume of Distribution (Vz/F);   Plasma Decay Half-Life (t1/2);   Unbound Apparent Oral Clearance (CLu/F);   "Unbound Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0 - ∞)u]";   Unbound Maximum Observed Plasma Concentration (Cmaxu);   "Unbound Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClastu)";   fraction of unbound drug in plasma (fu);   Unbound Apparent Volume of Distribution (Vzu/F)
10 Unknown  Simvastatin Effect on End Stage Renal Failure Patients Treated by Peritoneal Dialysis
Conditions: Renal Failure, End Stage;   Peritoneal Dialysis
Intervention: Drug: Simvastatin
Outcome Measures: endothelial venodilation;   Inflammation markers (C-reactive protein, IL-6, TNF);   Lipoproteins;   Oxidative stress
11 Recruiting NGAL Predictive Value of Acute Kidney Failure After Cardiac Surgery in Patients With Preoperative Chronic Kidney Failure
Conditions: Preoperative KIDNEY FAILURE, CHRONIC;   Postoperative KIDNEY FAILURE, ACUTE;   Cardiac Surgical Procedures
Intervention:
Outcome Measure: Neutrophil Gelatinase Associated Lipocalin (NGAL) level
12 Recruiting Predictive Value of PIIINP and Urinary NGAL for the Development of Chronic Renal Failure in Patients With Cystic Fibrosis After Lung Transplantation (MUCO-IRC)
Conditions: Lung Transplantation;   Cystic Fibrosis;   Renal Failure
Intervention: Biological: Urinary levels of PIIINP and NGAL as a marker of changes in renal function
Outcome Measures: The correlation between the rate of urinary PIIINP inclusion in the study and the variation of the isotopic measurement of GFR over the 2 year study;   Description of histological lesions present after transplantation from renal biopsies performed in all patients with chronic Renal Failure defined by a GFR between 30 and 60 ml / min and / or proteinuria> 1 g / d.;   Correlation between the rate of PIIINP urinary NGAL and the rate of first and second intensity of renal fibrosis histologically assessed renal biopsies that have been conducted in patients.;   Correlation between the rate of urinary PIIINP and glomerular filtration rate measured by scintigraphy Chrome-EDTA at study entry and after 2 years of follow-up;   Correlation between the rate of urinary NGAL and GFR measured by scintigraphy Chrome-EDTA at study entry and after 2 years of follow-up;   Correlation between the rate of urinary NGAL to the inclusion in the study and the variation of the isotopic measurement of GFR over the 2 year study.
13 Unknown  N-Acetylcysteine in Heart Failure With Coexistent Chronic Renal Failure
Conditions: Heart Failure, Congestive;   Kidney Failure, Chronic
Intervention: Drug: N-acetylcysteine
Outcome Measures: Vascular function via non invasive ultrasound measured flow mediated dilatation;   Estimated glomerular filtration rate calculated with Cockroft Gault equation.;   Symptoms of heart failure;   Death;   Serum BNP (brain natriuretic peptide)
14 Recruiting Effects of Dexmedetomidine Premedication on Geriatric Patients With Chronic Renal Failure Undergoing Hip Surgery
Conditions: Chronic Renal Failure;   Hip Fracture
Interventions: Drug: dexmedetomidine infusion for premedication;   Drug: Midazolam;   Drug: saline infusion;   Drug: Spinal block with hyperbaric bupivacaine 0.5% 12.5 mg
Outcome Measure: Decrease at the propofol doses and postoperative early recovery
15 Unknown  Study of Clinical Non-inferiority of Actparin® (Laboratorio Bergamo) Compared to Heparin Sodium (APP Pharmaceuticals), in Patients With Chronic Renal Failure
Condition: Chronic Renal Failure
Intervention: Biological: heparin sodium
Outcome Measures: Effectiveness in prevention of clotting in the extracorporeal circuit during hemodialysis;   Pharmacodynamic activity of heparin observed through aPTT marker;   Safety in use of heparin by monitoring adverse events
16 Unknown  The Use of Nesiritide in Thoracic Aneurysm Repair to Prevent Acute Renal Failure
Conditions: Cardiovascular Disease;   Acute Renal Failure;   Death
Intervention: Drug: Nesiritide
Outcome Measures: Need for dialysis and/or mortality;   Rise in serum creatinine;   blood urea nitrogen
17 Recruiting Study to Assess the Safety and Effects of Autologous Adipose-Derived Stromal Cells Delivered in Patients With Renal Failure
Condition: Renal Failure
Intervention: Procedure: Harvesting and Isolation of Stem cells
Outcome Measures: Significant clinical improvement in serum creatinine and urine output (improvement in measured Glomerular Filtration Rate(GFR) by 50%);   number of participants with adverse events;   Significant clinical improvement in serum creatinine and urine output (improvement in measured Glomerular Filtration Rate(GFR) by 50%) at 6 months;   Improvement in renal biopsy measured by the reduction of scarring etc as compared to baseline
18 Not yet recruiting Obesity Surgery and Kidney Transplant for Patients With Obesity and Renal Failure
Conditions: Severe Obesity;   Renal Failure
Interventions: Procedure: Gastric Bypass;   Other: Weight Loss Program
Outcome Measures: Ability to reach medical suitability for renal transplant within 18 months after initiating treatment and the change and trajectory of health-related quality of life (HRQOL);   All-cause mortality;   Weight loss;   Surgical outcomes;   Development or regression of diabetes;   Development or regression of other comorbidities;   Health care utilization;   Nutritional status;   Hormonal and metabolic status
19 Recruiting Search for New Methods to Detect Acute Renal Failure
Condition: Kidney Failure
Intervention:
Outcome Measures: To find new bio-markers of renal injury, its progression or recovery.;   The new assay of MSD might facilitate the translation of novel biomarker from bench to bedside.
20 Recruiting The Correlation Between HbA1c and Mean Blood Glucose in Patients With Diabetes and Renal Failure
Conditions: Diabetes;   Renal Failure
Intervention:
Outcome Measure: Correlation

These studies may lead to new treatments and are adding insight into Metoprolol Tartrate etiology and treatment.

A major focus of Metoprolol Tartrate research is the development of new drugs and other treatment options. Studies seek to identify new drugs to treat various related disorders and to find safer, more effective doses for medications already being used. Other research is aimed at identifying receptors or drug targets.


Discuss Metoprolol Tartrate